Emcure Pharma launches Poviztra, India’s newest weight-loss injection in booming obesity drug market
Emcure Pharma, led by CEO and Managing Director Satish Mehta, has partnered with Novo Nordisk to introduce Poviztra, a new weight-loss drug, to the Indian stock market of anti-obesity drugs, driven by the introduction of finance-based therapies like Poviztra and Novo Nordisk's Wegovy.
Poviztra, a semaglutide injection, is available in a once-weekly pen device, offering five doses and a maintenance dosing of 2.4 mg. Its effectiveness is evident from clinical trials, where one in three participants on Wegovy, a similar drug, experienced weight loss of over 20%.
The Indian anti-obesity drug market has witnessed remarkable growth, reaching Rs 628 crore in the twelve months ending June 2025, a fivefold increase over five years. While Wegovy's 2.4 mg dose is priced at Rs 26,015 for a month's supply, Poviztra's pricing remains undisclosed. Emcure Pharma will be the exclusive distributor and marketer of Poviztra in India, aiming to tap into this expanding stock market.
The partnership between Novo Nordisk and Emcure Pharma brings a new hope, Poviztra, to the Indian market for food management and reducing cardiovascular risks. With the market's significant growth and the proven effectiveness of similar drugs, Emcure Pharma, under Satish Mehta's leadership, is poised to make a substantial impact in this sector.
